The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The UniProt accession P35498 corresponds to human SCN1A, encoding the pore‑forming α subunit of the voltage‑gated sodium channel NaV1.1. Multiple recent reviews and primary studies converge on a core functional model in which NaV1.1 is especially important for action potential firing in GABAergic inhibitory interneurons (notably parvalbumin‑positive fast‑spiking interneurons). Loss‑of‑function (LoF)/haploinsufficiency reduces inhibitory output and disrupts excitation–inhibition balance, producing epileptic phenotypes such as Dravet syndrome, whereas gain‑of‑function (GoF) variants can cause distinct early‑onset encephalopathies or migraine phenotypes with different pharmacologic implications. (fan2023clinicalandgenetic pages 13-15, barbieri2023voltagegatedsodiumchannel pages 4-6, clatot2023scn1again‐of‐functionmutation pages 1-3, mouhi2024thegeneticfacets pages 1-2)
| Category | Summary for SCN1A / Nav1.1 (UniProt P35498) | Key source | Publication date | URL | Citation |
|---|---|---|---|---|---|
| Verified identity | SCN1A encodes voltage-gated sodium channel alpha subunit Nav1.1 in Homo sapiens; a pore-forming VGSC/Nav alpha subunit of the sodium channel family, highly relevant in the CNS and especially inhibitory interneurons. This matches UniProt P35498 naming and family assignment. | Fan et al., Int J Mol Sci; Barbieri et al., Life | Dec 2023; May 2023 | https://doi.org/10.3390/ijms25010031 ; https://doi.org/10.3390/life13051191 | (fan2023clinicalandgenetic pages 13-15, barbieri2023voltagegatedsodiumchannel pages 2-4) |
| Molecular function | Nav1.1 is a voltage-gated Na+ channel that opens with membrane depolarization to carry inward sodium current needed for action potential initiation/propagation. Canonical structure: 4 homologous domains (DI–DIV), each with S1–S6; S4 segments are voltage sensors, S5–S6 form the pore/selectivity pathway, and the DIII–DIV intracellular loop mediates fast inactivation. Functional dysfunction can be LOF (reduced current density/recovery) or GOF (persistent current, altered gating). | Fan et al., Int J Mol Sci; Barbieri et al., Life | Dec 2023; May 2023 | https://doi.org/10.3390/ijms25010031 ; https://doi.org/10.3390/life13051191 | (fan2023clinicalandgenetic pages 13-15, barbieri2023voltagegatedsodiumchannel pages 2-4) |
| Cellular localization | Nav1.1 is a plasma-membrane channel concentrated in the central nervous system, with strong functional importance in GABAergic inhibitory interneurons, including parvalbumin-positive fast-spiking interneurons. | Fan et al., Int J Mol Sci; Yuan et al., Brain | Dec 2023; Oct 2024 | https://doi.org/10.3390/ijms25010031 ; https://doi.org/10.1093/brain/awad349 | (fan2023clinicalandgenetic pages 13-15, yuan2024asorestoresexcitability pages 1-2) |
| Core physiological role | The best-supported physiological role is enabling high-frequency firing of inhibitory interneurons and thereby maintaining excitation–inhibition balance. In SCN1A haploinsufficiency, PV+ interneurons show reduced sodium current density, abnormal firing with depolarization block, and reduced GABAergic signaling onto pyramidal neurons; this disinhibits cortical networks and promotes seizures. | Yuan et al., Brain; Barbieri et al., Life | Oct 2024; May 2023 | https://doi.org/10.1093/brain/awad349 ; https://doi.org/10.3390/life13051191 | (yuan2024asorestoresexcitability pages 1-2, barbieri2023voltagegatedsodiumchannel pages 4-6, yuan2024asorestoresexcitability media 56316bcb) |
| Dravet syndrome | Major disease association: Dravet syndrome (DS) is usually caused by heterozygous LOF / haploinsufficiency of SCN1A. Reported estimates in recent reviews: ~85–90% of DS is attributable to SCN1A variants; incidence about 1/22,000–1/49,900 live births. Mechanistically, reduced Nav1.1 function in inhibitory interneurons lowers inhibition and causes developmental and epileptic encephalopathy. | Mouhi et al., Ann Child Neurol; Fan et al., Int J Mol Sci; 2024 review/prize summary | Apr 2024; Dec 2023; 2024 | https://doi.org/10.26815/acn.2023.00367 ; https://doi.org/10.3390/ijms25010031 | (mouhi2024thegeneticfacets pages 1-2, fan2023clinicalandgenetic pages 13-15, reallife2024themackeithprize pages 7-8) |
| GEFS+ | Generalized epilepsy with febrile seizures plus (GEFS+) is a milder SCN1A-associated epilepsy spectrum than DS; SCN1A variants linked to GEFS+ are often less disruptive than DS truncating/haploinsufficient variants, though reduced interneuron excitability remains a key mechanism in many cases. | Barbieri et al., Life | May 2023 | https://doi.org/10.3390/life13051191 | (barbieri2023voltagegatedsodiumchannel pages 4-6) |
| Hemiplegic migraine | Familial hemiplegic migraine type 3 (FHM3) is associated with SCN1A GOF variants. Reported mechanisms include right-shifted inactivation, faster recovery, and increased persistent current, producing interneuron hyperactivity and increased susceptibility to cortical spreading depression rather than classic Dravet-like haploinsufficiency. | Barbieri et al., Life | May 2023 | https://doi.org/10.3390/life13051191 | (barbieri2023voltagegatedsodiumchannel pages 4-6, barbieri2023voltagegatedsodiumchannel pages 14-15) |
| Early-onset DEE GOF example | A recurrent SCN1A p.R1636Q variant defines a distinct early-onset developmental and epileptic encephalopathy with mixed GOF, including slowed inactivation and prominent late sodium current. Unlike LOF/Dravet, a sodium-channel blocker (oxcarbazepine) partially corrected electrophysiologic abnormalities and helped one patient clinically. | Clatot et al., Epilepsia | Nov 2023 | https://doi.org/10.1111/epi.17444 | (clatot2023scn1again‐of‐functionmutation pages 1-3) |
| Established treatment implications | In LOF/Dravet, sodium-channel blockers can worsen seizures and are generally avoided; therapies that enhance inhibitory tone are preferred. Recent reviews identify fenfluramine as established in clinical practice, alongside stiripentol, cannabidiol, valproate, and clobazam for many patients. | Specchio et al., Lancet Child Adolesc Health; Mouhi et al., Ann Child Neurol; Clatot et al., Epilepsia | Nov 2024; Apr 2024; Nov 2023 | https://doi.org/10.1016/S2352-4642(24)00196-2 ; https://doi.org/10.26815/acn.2023.00367 ; https://doi.org/10.1111/epi.17444 | (specchio2024theexpandingfield pages 27-29, mouhi2024thegeneticfacets pages 1-2, clatot2023scn1again‐of‐functionmutation pages 1-3) |
| Fenfluramine: current implementation | Fenfluramine is now used in real-world DS practice and is recommended as an early-line option in recent guidance. Real-world Polish data reported >70% seizure reduction in one detailed case, normalization of EEG, and developmental/ataxia improvement; the same cohort described significant clinical improvement in 3/3 patients started on fenfluramine in 2023–2024. | Wirrell et al., Epilepsia Open; Zielińska et al., Biomedicines | Jul 2024; Jun 2024 | https://doi.org/10.1002/epi4.12998 ; https://doi.org/10.3390/biomedicines12061249 | (zielinska2024howhasthe pages 2-4) |
| Emerging disease-modifying therapy: ASO | STK-001 / ASO-22 is an antisense strategy designed to increase productive SCN1A transcript by preventing inclusion of poison exon 20N from the healthy allele (TANGO approach). In mouse models, related ASO treatment restored PV+ interneuron firing, sodium current density, and GABAergic signaling, and prior work reduced electrographic seizures and SUDEP. Ongoing clinical programs include MONARCH (NCT04442295) and ADMIRAL. | Yuan et al., Brain; 2024 ASO/clinical summary | Oct 2024; 2024 | https://doi.org/10.1093/brain/awad349 | (yuan2024asorestoresexcitability pages 1-2, reallife2024themackeithprize pages 7-8, yuan2024asorestoresexcitability media 56316bcb) |
| Emerging gene therapy / CRISPRa | 2024 expert reviews highlight viral-vector Nav1.1 replacement, dCas9-based SCN1A activation, and cell-selective AAV-mediated SCN1A regulation as promising disease-modifying concepts. Preclinical studies cited in review literature show rescue of interneuron excitability, seizure phenotypes, and mortality in Dravet models, with some tolerability signals in nonhuman primates. | Specchio et al., Lancet Child Adolesc Health | Nov 2024 | https://doi.org/10.1016/S2352-4642(24)00196-2 | (specchio2024theexpandingfield pages 27-29) |
| Long-term outcomes and burden | In a 10-year prospective SCN1A-positive DS cohort (68/113 caregivers responded), developmental status worsened from mean 2.9 to 4.45 severity rating (P < 0.001) even as epilepsy severity modestly improved. Comorbidities increased: autistic features 30%→77%, behavioral problems 38%→81%, motor/mobility problems 41%→80%. >90% of caregivers reported negative impacts on their own health/career, and 35% had never discussed SUDEP with a clinician. | Feng et al., Brain Communications | Jan 2024 | https://doi.org/10.1093/braincomms/fcae004 | (feng2024longtermpredictorsof pages 1-3) |
| Additional quantitative disease statistics | Recent sources report SUDEP risk up to 20% in Dravet syndrome and a US prevalence estimate as high as 1:15,700 (~20,000 individuals). In one retrospective cohort of 138 Chinese children with SCN1A mutations, 77% had first seizure before 7 months, 72% had febrile convulsions lasting >15 min, 67% had multiple febrile seizures within 24 h, and fever accompanied 80% of events. | Yuan et al., Brain; Mouhi et al., Ann Child Neurol | Oct 2024; Apr 2024 | https://doi.org/10.1093/brain/awad349 ; https://doi.org/10.26815/acn.2023.00367 | (yuan2024asorestoresexcitability pages 1-2, mouhi2024thegeneticfacets pages 1-2) |
Table: This table summarizes verified identity, function, localization, disease mechanisms, and translational relevance for human SCN1A/Nav1.1 using recent authoritative sources. It is useful as a compact evidence map linking molecular function to clinical phenotypes and emerging therapies.
SCN1A encodes NaV1.1, a voltage‑gated Na+ channel α subunit that forms the ion‑conducting pore and contains the canonical sodium‑channel architecture: four homologous domains (DI–DIV) with S1–S6 transmembrane helices per domain; S4 helices act as primary voltage sensors, and the DIII–DIV intracellular loop is central to fast inactivation. (fan2023clinicalandgenetic pages 13-15, barbieri2023voltagegatedsodiumchannel pages 2-4)
NaV1.1 is an electrogenic ion channel whose key “substrate” is Na+, conducting inward sodium current upon depolarization to enable action potential initiation/propagation and support high‑frequency firing in specific neuronal populations. (fan2023clinicalandgenetic pages 13-15, barbieri2023voltagegatedsodiumchannel pages 2-4)
Recent reviews explicitly distinguish:
- LoF: decreased current density, impaired recovery, reduced availability, or other changes reducing excitability. (barbieri2023voltagegatedsodiumchannel pages 2-4)
- GoF: shifts in activation/inactivation and/or increased persistent/late currents producing hyperexcitability. (barbieri2023voltagegatedsodiumchannel pages 2-4, clatot2023scn1again‐of‐functionmutation pages 1-3)
For SCN1A, the clinical impact of LoF versus GoF is not symmetric: LoF classically drives Dravet‑spectrum disease, whereas GoF is increasingly recognized as a mechanistically distinct cause of developmental epileptic encephalopathy in some cases and may require different antiseizure pharmacology. (clatot2023scn1again‐of‐functionmutation pages 1-3, fan2023clinicalandgenetic pages 13-15)
NaV1.1 is described as predominantly CNS‑expressed with functional enrichment in inhibitory GABAergic interneurons, including parvalbumin‑positive (PV+) fast‑spiking interneurons. (fan2023clinicalandgenetic pages 13-15, yuan2024asorestoresexcitability pages 1-2)
A key mechanistic model (supported by 2024 primary electrophysiology in a Dravet mouse model) is:
- In Scn1a+/− mice, cortical pyramidal neuron intrinsic excitability is largely unchanged, but PV+ interneurons show altered excitability with decreased sodium current density and a progression to hypoexcitability/depolarization block at higher drive. (yuan2024asorestoresexcitability pages 1-2)
- Reduced PV+ function corresponds to reduced GABAergic signaling onto pyramidal neurons, consistent with impaired inhibitory tone as a proximal driver of network hyperexcitability. (yuan2024asorestoresexcitability pages 1-2)
These findings align with earlier/ongoing synthesis that Dravet syndrome is an “interneuronopathy” caused by impaired Nav1.1‑dependent firing and synaptic inhibition, generating seizures and downstream neurodevelopmental impairment. (barbieri2023voltagegatedsodiumchannel pages 4-6, barbieri2023voltagegatedsodiumchannel pages 14-15)
SCN1A/NaV1.1 sits directly in the membrane excitability/action‑potential pathway, contributing to the ionic currents that shape spike initiation and high‑frequency firing, especially within inhibitory circuit elements that stabilize cortical/hippocampal network dynamics. (barbieri2023voltagegatedsodiumchannel pages 2-4, fan2023clinicalandgenetic pages 13-15)
Dravet syndrome (DS) is a developmental and epileptic encephalopathy with seizures beginning in the first year of life; recent reviews estimate DS incidence around 1/22,000 to 1/49,900 live births, and attribute ~90% of DS to SCN1A variants (usually de novo). (mouhi2024thegeneticfacets pages 1-2)
Multiple sources describe DS as primarily an SCN1A LoF/haploinsufficiency disorder in which impaired inhibitory interneuron firing reduces inhibition and produces network hyperexcitability. (fan2023clinicalandgenetic pages 13-15, barbieri2023voltagegatedsodiumchannel pages 4-6)
Additional DS quantitative burden includes SUDEP risk up to ~20% and prevalence estimates as high as 1:15,700 in the US in a recent mechanistic/therapeutic study focused on SCN1A augmentation. (yuan2024asorestoresexcitability pages 1-2)
A 10‑year prospective follow‑up of an SCN1A‑positive DS cohort (UK; 68/113 caregiver respondents) reported that developmental outcome worsened substantially over a decade even as epilepsy severity modestly improved. Comorbidities increased markedly: autistic features 30%→77%, behavioral problems 38%→81%, and motor/mobility problems 41%→80% (all P<0.001). (feng2024longtermpredictorsof pages 1-3)
Reviews summarize that GEFS+ is associated with ~50 SCN1A mutations and is generally milder and more drug responsive than DS, though reduced interneuron excitability remains a recurring mechanistic theme. (barbieri2023voltagegatedsodiumchannel pages 4-6)
Familial hemiplegic migraine type 3 (FHM3) is described as caused by SCN1A variants with GoF biophysical signatures (e.g., increased persistent current; altered inactivation), and animal models show altered interneuron activity with lowered threshold for cortical spreading depression—distinct from DS LoF pathophysiology. (barbieri2023voltagegatedsodiumchannel pages 4-6)
A 2023 Epilepsia study characterized a recurrent SCN1A p.R1636Q variant causing early‑onset DEE and demonstrated a mixed GoF pattern with slowed inactivation and prominent late sodium current; importantly, oxcarbazepine partially corrected electrophysiologic abnormalities and was clinically beneficial in one individual—contrasting with the typical contraindication of sodium‑channel blockers in SCN1A LoF/DS. (clatot2023scn1again‐of‐functionmutation pages 1-3)
A 2024 primary study in Brain investigated an antisense oligonucleotide (ASO) strategy (surrogate ASO‑84 for STK‑001/ASO‑22) targeting SCN1A poison exon 20N inclusion, designed to increase productive transcript and NaV1.1 expression. In Scn1a+/− mice, a single early intracerebroventricular dose restored PV+ interneuron firing, restored sodium current density, and normalized GABAergic signaling to pyramidal neurons, supporting a mechanism‑aligned precision therapy strategy for haploinsufficiency. (yuan2024asorestoresexcitability pages 1-2)
Figures retrieved from this study provide quantitative visual support for (i) interneuron firing rescue, (ii) restored inhibitory synaptic signaling, and (iii) restored sodium current density. (yuan2024asorestoresexcitability media 56316bcb, yuan2024asorestoresexcitability media ce549bc3, yuan2024asorestoresexcitability media fe492d0d, yuan2024asorestoresexcitability media ab75e01c)
A 2024 Lancet Child & Adolescent Health review summarizes translational directions for genetic DEEs, including SCN1A LoF disorders, and highlights preclinical evidence for viral vector–mediated NaV1.1 expression and dCas9‑based SCN1A activation restoring interneuron excitability and attenuating seizures in Dravet models, with additional emphasis on cell‑selective AAV regulation and tolerability signals in nonhuman primates. (specchio2024theexpandingfield pages 27-29)
Recent reviews emphasize actionable treatment stratification based on SCN1A mechanism: for LoF/Dravet, avoid sodium‑channel blockers (which may worsen seizures), whereas certain GoF SCN1A encephalopathies may respond to sodium‑channel inhibitors. (fan2023clinicalandgenetic pages 13-15, clatot2023scn1again‐of‐functionmutation pages 1-3)
A 2024 clinical practice review (Epilepsia Open, July 2024) states fenfluramine is approved for seizures associated with DS/LGS in patients ≥2 years in the US and as add‑on in EU/UK/Japan and describes serotonergic and sigma‑1 receptor activity. It summarizes comparative efficacy evidence from a network meta‑analysis ranking probability of ≥50% seizure reduction as fenfluramine > stiripentol > cannabidiol (ES 0.715 vs 0.604 vs 0.448, respectively) and provides practical dosing guidance (e.g., start 0.2 mg/kg/day; commonly ~0.4 mg/kg/day; capped daily doses depend on stiripentol co‑therapy). (wirrell2024practicalconsiderationsfor pages 2-4, wirrell2024practicalconsiderationsfor pages 8-9)
A 2024 Polish single‑center retrospective report described real‑world introduction of fenfluramine (available in Poland since 2023 via emergency access) in three DS patients, with one detailed case reporting >70% seizure reduction, EEG normalization, and developmental/ataxia improvements after fenfluramine initiation in 2024. (zielinska2024howhasthe pages 2-4)
A 2024 systematic review/meta‑analysis (Frontiers in Neurology, July 2024) pooled 16 trials (n=173) and estimated a ≥50% seizure reduction responder rate of 0.54 (95% CI 0.43–0.65), with timepoint responder rates of 0.42 at 3 months, 0.54 at 6 months, 0.51 at 12 months, and 0.49 at 24 months. The authors note VNS appears beneficial for children with SCN1A abnormalities but emphasize low‑quality evidence and the need for RCTs. (chen2024vagusnervestimulation pages 1-2, chen2024vagusnervestimulation pages 6-9)
Multiple recent authoritative reviews (2023–2024) converge that SCN1A LoF reduces firing in inhibitory interneurons and that sodium‑channel blockers should be avoided in classic Dravet syndrome, reinforcing a mechanism‑guided clinical heuristic. (specchio2024theexpandingfield pages 27-29, fan2023clinicalandgenetic pages 13-15, barbieri2023voltagegatedsodiumchannel pages 4-6)
Authoritative synthesis in 2024 places SCN1A among leading examples where genetic clarity enables precision modalities: ASOs to augment transcript output and AAV/dCas9 approaches to increase NaV1.1 expression in relevant neuronal populations. (specchio2024theexpandingfield pages 27-29, yuan2024asorestoresexcitability pages 1-2)
A 2024 preprint proposes a Bayesian ACMG/AMP‑calibrated framework to translate heterogeneous electrophysiology outcomes into standardized evidence for variant pathogenicity. In their dataset, the authors analyzed 216 functional assessments across 191 variants, including SCN1A (n=74). They report which electrophysiology parameters most often drive GoF/LoF classification and define conditions for Strong evidence as likelihood ratio >18.7 under ACMG/AMP. They further introduce FENICS, a 152‑term ontology, and report that ClinVar contains 1,731 standardized annotations across a 271‑variant combined set (SCN1A/2A/3A/8A and KCNQ2). (parthasarathy2024optimizingclinicalinterpretability pages 1-3)
References
(fan2023clinicalandgenetic pages 13-15): Hueng-Chuen Fan, Ming-Tao Yang, Lung-Chang Lin, Kuo-Liang Chiang, and Chuan-Mu Chen. Clinical and genetic features of dravet syndrome: a prime example of the role of precision medicine in genetic epilepsy. International Journal of Molecular Sciences, 25:31, Dec 2023. URL: https://doi.org/10.3390/ijms25010031, doi:10.3390/ijms25010031. This article has 28 citations.
(barbieri2023voltagegatedsodiumchannel pages 4-6): Raffaella Barbieri, Mario Nizzari, Ilaria Zanardi, Michael Pusch, and Paola Gavazzo. Voltage-gated sodium channel dysfunctions in neurological disorders. Life, 13:1191, May 2023. URL: https://doi.org/10.3390/life13051191, doi:10.3390/life13051191. This article has 80 citations.
(clatot2023scn1again‐of‐functionmutation pages 1-3): Jérôme Clatot, Shridhar Parthasarathy, Stacey Cohen, Jillian L. McKee, Shavonne Massey, Ala Somarowthu, Ethan M. Goldberg, and Ingo Helbig.
(mouhi2024thegeneticfacets pages 1-2): Hinde El Mouhi, Meriame Abbassi, Meryem Jalte, Abdelhafid Natiq, Laila Bouguenouch, and Sana Chaouki. The genetic facets of dravet syndrome: recent insights. Annals of Child Neurology, 32:67-82, Apr 2024. URL: https://doi.org/10.26815/acn.2023.00367, doi:10.26815/acn.2023.00367. This article has 5 citations.
(barbieri2023voltagegatedsodiumchannel pages 2-4): Raffaella Barbieri, Mario Nizzari, Ilaria Zanardi, Michael Pusch, and Paola Gavazzo. Voltage-gated sodium channel dysfunctions in neurological disorders. Life, 13:1191, May 2023. URL: https://doi.org/10.3390/life13051191, doi:10.3390/life13051191. This article has 80 citations.
(yuan2024asorestoresexcitability pages 1-2): Yukun Yuan, Luis Lopez-Santiago, Nicholas Denomme, Chunling Chen, Heather A O'Malley, Samantha L Hodges, Sophina Ji, Zhou Han, Anne Christiansen, and Lori L Isom. Aso restores excitability, gaba signalling and sodium current density in a model of dravet syndrome. Brain : a journal of neurology, 147:1231-1246, Oct 2024. URL: https://doi.org/10.1093/brain/awad349, doi:10.1093/brain/awad349. This article has 51 citations.
(yuan2024asorestoresexcitability media 56316bcb): Yukun Yuan, Luis Lopez-Santiago, Nicholas Denomme, Chunling Chen, Heather A O'Malley, Samantha L Hodges, Sophina Ji, Zhou Han, Anne Christiansen, and Lori L Isom. Aso restores excitability, gaba signalling and sodium current density in a model of dravet syndrome. Brain : a journal of neurology, 147:1231-1246, Oct 2024. URL: https://doi.org/10.1093/brain/awad349, doi:10.1093/brain/awad349. This article has 51 citations.
(reallife2024themackeithprize pages 7-8): HIEH Real-Life. The mackeith prize for bpna 2024 has been awarded to dr dora steel. Unknown journal, 2024.
(barbieri2023voltagegatedsodiumchannel pages 14-15): Raffaella Barbieri, Mario Nizzari, Ilaria Zanardi, Michael Pusch, and Paola Gavazzo. Voltage-gated sodium channel dysfunctions in neurological disorders. Life, 13:1191, May 2023. URL: https://doi.org/10.3390/life13051191, doi:10.3390/life13051191. This article has 80 citations.
(specchio2024theexpandingfield pages 27-29): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 30 citations.
(zielinska2024howhasthe pages 2-4): Anita Zielińska, Urszula Skarżyńska, Paulina Górka-Skoczylas, Tomasz Mazurczak, Aleksandra Kuźniar-Pałka, Karolina Kanabus, Dorota Hoffman-Zacharska, and Elżbieta Stawicka. How has the treatment of polish children with dravet syndrome changed? future perspectives. Biomedicines, 12:1249, Jun 2024. URL: https://doi.org/10.3390/biomedicines12061249, doi:10.3390/biomedicines12061249. This article has 1 citations.
(feng2024longtermpredictorsof pages 1-3): Tony Feng, Phoebe Makiello, Benjamin Dunwoody, Felix Steckler, Joseph D Symonds, Sameer M Zuberi, Liam Dorris, and Andreas Brunklaus. Long-term predictors of developmental outcome and disease burden in scn1a-positive dravet syndrome. Brain Communications, Jan 2024. URL: https://doi.org/10.1093/braincomms/fcae004, doi:10.1093/braincomms/fcae004. This article has 22 citations and is from a peer-reviewed journal.
(yuan2024asorestoresexcitability media ce549bc3): Yukun Yuan, Luis Lopez-Santiago, Nicholas Denomme, Chunling Chen, Heather A O'Malley, Samantha L Hodges, Sophina Ji, Zhou Han, Anne Christiansen, and Lori L Isom. Aso restores excitability, gaba signalling and sodium current density in a model of dravet syndrome. Brain : a journal of neurology, 147:1231-1246, Oct 2024. URL: https://doi.org/10.1093/brain/awad349, doi:10.1093/brain/awad349. This article has 51 citations.
(yuan2024asorestoresexcitability media fe492d0d): Yukun Yuan, Luis Lopez-Santiago, Nicholas Denomme, Chunling Chen, Heather A O'Malley, Samantha L Hodges, Sophina Ji, Zhou Han, Anne Christiansen, and Lori L Isom. Aso restores excitability, gaba signalling and sodium current density in a model of dravet syndrome. Brain : a journal of neurology, 147:1231-1246, Oct 2024. URL: https://doi.org/10.1093/brain/awad349, doi:10.1093/brain/awad349. This article has 51 citations.
(yuan2024asorestoresexcitability media ab75e01c): Yukun Yuan, Luis Lopez-Santiago, Nicholas Denomme, Chunling Chen, Heather A O'Malley, Samantha L Hodges, Sophina Ji, Zhou Han, Anne Christiansen, and Lori L Isom. Aso restores excitability, gaba signalling and sodium current density in a model of dravet syndrome. Brain : a journal of neurology, 147:1231-1246, Oct 2024. URL: https://doi.org/10.1093/brain/awad349, doi:10.1093/brain/awad349. This article has 51 citations.
(wirrell2024practicalconsiderationsfor pages 2-4): Elaine C. Wirrell, Lieven Lagae, Ingrid E. Scheffer, J. Helen Cross, Nicola Specchio, and Adam Strzelczyk. Practical considerations for the use of fenfluramine to manage patients with dravet syndrome or lennox–gastaut syndrome in clinical practice. Epilepsia Open, 9:1643-1657, Jul 2024. URL: https://doi.org/10.1002/epi4.12998, doi:10.1002/epi4.12998. This article has 21 citations and is from a peer-reviewed journal.
(wirrell2024practicalconsiderationsfor pages 8-9): Elaine C. Wirrell, Lieven Lagae, Ingrid E. Scheffer, J. Helen Cross, Nicola Specchio, and Adam Strzelczyk. Practical considerations for the use of fenfluramine to manage patients with dravet syndrome or lennox–gastaut syndrome in clinical practice. Epilepsia Open, 9:1643-1657, Jul 2024. URL: https://doi.org/10.1002/epi4.12998, doi:10.1002/epi4.12998. This article has 21 citations and is from a peer-reviewed journal.
(chen2024vagusnervestimulation pages 1-2): Shuang Chen, Man Li, and Ming Huang. Vagus nerve stimulation for the therapy of dravet syndrome: a systematic review and meta-analysis. Frontiers in Neurology, Jul 2024. URL: https://doi.org/10.3389/fneur.2024.1402989, doi:10.3389/fneur.2024.1402989. This article has 8 citations and is from a peer-reviewed journal.
(chen2024vagusnervestimulation pages 6-9): Shuang Chen, Man Li, and Ming Huang. Vagus nerve stimulation for the therapy of dravet syndrome: a systematic review and meta-analysis. Frontiers in Neurology, Jul 2024. URL: https://doi.org/10.3389/fneur.2024.1402989, doi:10.3389/fneur.2024.1402989. This article has 8 citations and is from a peer-reviewed journal.
(parthasarathy2024optimizingclinicalinterpretability pages 1-3): Shridhar Parthasarathy, Stacey R. Cohen, Eryn Fitch, Priya Vaidiswaran, Sarah Ruggiero, Laina Lusk, Victoria Chisari, David Lewis-Smith, Stephan Lauxmann, Christian M. Boßelmann, Christopher H. Thompson, Eric R. Wengert, Ulrike Hedrich, Shiva Ganesan, Ganna Balagura, Roland Krause, Julie Xian, Peter Galer, Manuela Pendziwiat, Eduardo Perez-Palma, Mauno Vihinen, Jennifer Hart, Melissa J. Landrum, Dennis Lal, Edward C. Cooper, Holger Lerche, Ethan Goldberg, Andreas Brunklaus, Carlos G. Vanoye, Stephanie Schorge, Alfred L. George, and Ingo Helbig. Optimizing clinical interpretability of functional evidence in epilepsy-related ion channel variants. bioRxiv, May 2024. URL: https://doi.org/10.1101/2024.05.09.593343, doi:10.1101/2024.05.09.593343. This article has 2 citations.